Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lymphoma patients: drug duo aims to shrink tumors

NCT ID NCT06390956

Recruiting now Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two drugs, pirtobrutinib and rituximab, can shrink or eliminate tumors in people newly diagnosed with marginal zone lymphoma. About 23 adults will receive the combination and be checked for response after several cycles. The goal is to control the disease, not to cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huntsman Cancer Institute at University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Washington University

    RECRUITING

    St Louis, Missouri, 63130, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact